PRINCETON, NJ -- (MARKET WIRE) -- November 10, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a
pharmaceutical company developing and commercializing products in the field
of dermatology, today announced that the putative securities class action
lawsuit filed against the company, certain of its officers and certain of
the underwriters for the company's 2004 initial public offering and 2005
secondary offering has been voluntarily dismissed, in its entirety and with
prejudice, by the lead plaintiffs' counsel.

The lead plaintiffs' counsel submitted the stipulation of dismissal to the
United States District Court for the District of New Jersey, without any
payment by the company or any of the defendants to the plaintiffs or their
counsel. The company expects the court to enter an order with respect to
the submission promptly.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the
development and commercialization of products in the field of dermatology.
Barrier Therapeutics currently markets three pharmaceutical products in the
United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25%
miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and
Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier
Therapeutics has other product candidates in various stages of clinical
development for the treatment of a range of dermatological conditions,
including acne, psoriasis, onychomycosis and other fungal infections such
as tinea versicolor. The company is headquartered in Princeton, New Jersey
and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.
More information about Barrier Therapeutics can be found on its corporate
website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.